Tech Center 1600 • Art Units: 1617 1622 1627
This examiner grants 40% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18025052 | MEPYRAMINE FOR USE IN THE TOPICAL TREATMENT OF NEUROPATHIC PAIN | Non-Final OA | Centre National de la Recherche Scientifique |
| 19094303 | METHODS FOR ENHANCING THE BIOAVAILABILITY AND EXPOSURE OF A VOLTAGE-GATED POTASSIUM CHANNEL OPENER | Non-Final OA | Xenon Pharmaceuticals Inc. |
| 18679045 | METHODS FOR ENHANCING THE BIOAVAILABILITY AND EXPOSURE OF A VOLTAGE-GATED POTASSIUM CHANNEL OPENER | Non-Final OA | Xenon Pharmaceuticals Inc. |
| 18648049 | METHODS FOR ENHANCING THE BIOAVAILABILITY AND EXPOSURE OF A VOLTAGE-GATED POTASSIUM CHANNEL OPENER | Non-Final OA | Xenon Pharmaceuticals Inc. |
| 19079370 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING OSTEOARTHRITIS | Non-Final OA | INSIGNIA PHARMACEUTICALS, LLC |
| 17622395 | EXTERNAL PREPARATION FOR SKIN | Final Rejection | KAO CORPORATION |
| 17925775 | Methods and Compositions for Treating Pain While Minimizing the Risk of Opioid Addiction | Non-Final OA | The United States Government as Represented by the Department of Veterans Affairs |
| 17534888 | SHIKIMATE ANALOGUES AND METHODS OF USE | Final Rejection | The Board of Regents of the University of Oklahoma |
| 18089651 | TOPICAL FORMULATION FOR A JAK INHIBITOR | Non-Final OA | Incyte Corporation |
| 16446718 | Process For Formation of Emulsion Containing Liquid Crystal Structure | Non-Final OA | Kenvue Brands LLC |
| 16854969 | LONG CHAIN FATTY ACID FORMULATIONS AND THEIR USE IN INHIBITING SALMONELLA INFECTION | Non-Final OA | CORNELL UNIVERSITY |
| 17443766 | STABLE AQUEOUS INJECTABLE SOLUTION OF EPINEPHRINE | Final Rejection | Sun Pharmaceutical Industries Limited |
| 18598526 | PHARMACEUTICAL COMPOSITIONS OF TOFACITINIB FOR ORAL ADMINISTRATION | Non-Final OA | HIKMA PHARMACEUTICALS USA INC. |
| 18495265 | COMPOSITION OF AND METHOD FOR TREATING INJURY AND/OR SKIN CONDITIONS | Non-Final OA | Omeza Holdings, Inc. |
| 18107179 | Pharmaceutical Formulation for Histone Deacetylase Inhibitors | Non-Final OA | Medivir AB |
| 18345760 | Method and Formulation for Improving Roflumilast Skin Penetration Lag Time | Non-Final OA | ARCUTIS Biotherapeutics, Inc. |
| 18044358 | DERMAL COMPOSITIONS REPLICATING THE VERNIX CASEOSA | Non-Final OA | APR Applied Pharma Research SA |
| 18001313 | BIOAVAILABLE SUGAR-BASED DICLOFENAC FORMULATIONS | Non-Final OA | APR Applied Pharma Research SA |
| 17981038 | PREVENTING OR MITIGATING CHEMOTHERAPY INDUCED ALOPECIA USING VITAMIN D | Non-Final OA | Berg LLC |
| 17997515 | FAST-ACTING TOPICAL ANESTHETIC FORMULATIONS | Non-Final OA | Achelon, Inc. |
| 17784243 | LIQUID PHARMACEUTICAL COMPOSITION COMPRISING CYTISINE | Final Rejection | Adamed Pharma S.A. |
| 17811347 | TREATMENT OF HAND ECZEMA | Final Rejection | LEO Pharma A/S |
| 17621614 | COMPOSITION COMPRISING POLAR LIPIDS AND METHOD OF MAKING SAME | Final Rejection | ALGANNOVATION LTD |
| 17441932 | INTRANASALLY ADMINISTERED ANTIHISTAMINES AND USES THEREOF | Final Rejection | DBBH, LLC |
| 17046764 | ABSCISIC ACID FOR THE TREATMENT OF SKIN DISEASES | Non-Final OA | VYTRUS BIOTECH, S.L. |
| 15931944 | ADMINISTRATION OF DEUTERATED CFTR POTENTIATORS | Non-Final OA | Vertex Pharmaceuticals (Europe) Limited |
| 16347587 | Therapeutic Cannabinoid Formulations and Methods for Their Use | Non-Final OA | Avidas Pharmaceuticals LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy